Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1756 to 1770 of 9100 results

  1. Nirogacestat for treating desmoid tumours [ID6453]

    In development Reference number: GID-TA11559 Expected publication date:  04 September 2026

    Technology appraisal guidance
    In development

  2. Nemtabrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma without a 17p deletion or TP53 mutation

    Awaiting development Reference number: GID-TA12036 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Nipocalimab for treating generalised myasthenia gravis in people 2 to 17 years

    Awaiting development Reference number: GID-TA12015 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

    Awaiting development Reference number: GID-TA11758 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]

    In development Reference number: GID-HST10063 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  6. Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]

    In development Reference number: GID-TA11701 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [ID6484]

    Awaiting development Reference number: GID-TA11632 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

    In development Reference number: GID-TA10752 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma ID6672

    In development Reference number: GID-TA11878 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Tislelizumab with platinum-based chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer at high risk of recurrence [ID6708]

    Awaiting development Reference number: GID-TA11953 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Palbociclib with anti-HER2 and endocrine therapies for maintenance treatment of hormone-receptor positive HER2-positive metastatic breast cancer [ID6251]

    Awaiting development Reference number: GID-TA11273 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

    In development Reference number: GID-TA11052 Expected publication date:  17 February 2027

    Technology appraisal guidance
    In development

  13. Prostate cancer: diagnosis and management (update)

    In development Reference number: GID-NG10451 Expected publication date:  17 December 2027

    NICE guideline
    In development

  14. Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer ID6573

    In development Reference number: GID-TA11755 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]

    In development Reference number: GID-TA11743 Expected publication date:  13 May 2027

    Technology appraisal guidance
    In development